Navigation Links
Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
Date:8/1/2014

AL INFORMATION This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to the exchange offer which Valeant has made to Allergan stockholders. The exchange offer is being made pursuant to a tender offer statement on Schedule TO (including the offer to exchange, the letter of election and transmittal and other related offer materials) and a registration statement on Form S-4 filed by Valeant with the SEC on June 18, 2014 and with the CSA, as each may be amended from time to time.  These materials contain important information, including the terms and conditions of the offer.  In addition, Valeant has filed a preliminary proxy statement with the SEC on June 24, 2014, as may be amended from time to time, Pershing Square Capital Management, L.P. ("Pershing Square") has filed a definitive solicitation statement with the SEC on July 11, 2014, and a preliminary proxy statement on July 23, 2014, and Valeant and Pershing Square (and, if a negotiated transaction is agreed, Allergan) may file one or more additional proxy statements or other documents with the SEC.  This communication is not a substitute for any proxy statement, registration statement, prospectus or other document Valeant, Pershing Square and/or Allergan have filed or may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF VALEANT AND ALLERGAN ARE URGED TO READ THE TENDER OFFER STATEMENT, REGISTRATION STATEMENT, AND ANY OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any definitive proxy statement(s) (if and when available) will be mailed to stockholders of Allergan and/or Valeant, as applicable. Investors and security holders may obtain free copies of the tender offer statement, the registration statement and other documents (if and when available)
'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Sciences, Inc., a,privately held biopharmaceutical company developing ... BSI-401 inhibited pancreatic cancer,cell growth in vitro ... combination with,oxaliplatin. BSI-401 is BiPar,s second-generation product ... as PARP (poly-ADP-ribose polymerase) inhibitors. Researchers ...
... sleep apnea and sleep behavior,disorders, ROCHESTER, Minn., ... diagnosing and treating patients with a,variety of sleep ... at CHEST 2007, the annual meeting of the ... 20-25. The following are,brief summaries of select presentations., ...
Cached Medicine Technology:BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 2Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 3Mayo Clinic Physicians Report Findings from Research on Sleep Disorders 4
(Date:12/25/2014)... 25, 2014 Product liability lawsuits filed ... recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in ... Order issued in the U.S. District Court, Northern District ... an open conference on January 7, 2015, at the ... in West Palm Beach, Florida. The Conference is scheduled ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... with complex chronic illnesses can receive effective, less expensive care ... easy access to a team of dedicated health care professionals, ... become seriously ill and need either hospitalization or a trip ... enhanced medical home clinic at the University of Texas in ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... Rosa, CA (PRWEB) December 25, 2014 ... department visits and 2 million hospital admissions across the ... and Prevention ). The CDC’s National Hospital Ambulatory ... departments through a survey conducted in 2010. They estimated ... department visits that resulted in a primary diagnosis of ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... is pleased to announce the opening of attendee registration ... Technology Exposition and Conference. This year,s event will be ... Stephens Convention Center in Rosemont, Illinois. OMTEC is the ... industry professionals involved in all facets of the supply ...
... year by a Cornell researcher add to growing evidence that ... of other fruits and vegetables -- can help keep the ... in the Journal of Agricultural and Food Chemistry ... and a member of Cornell,s Institute for Comparative and Environmental ...
... manifested in a variety of tissues and cancer cells ... being studied as a novel treatment. The PPAR-gamma ligand ... differentiation, apoptotic induction, and changes in genes or proteins ... been some reports suggesting that stomach cancer cells manifest ...
... been used as the "gold standard" for the assessment of ... possible complications of this procedure, for both, the physician and ... not trivial one. So, scientists tend to introduce non-invasive methods ... to be published on February 7, 2009 in the ...
... researcher Dr. Daniel Von Hoff and his team at ... developing novel therapies for patients with pancreatic cancer. They ... vulnerability." Dr. Von Hoff provides case studies and ... promising discoveries and is changing the future of oncology ...
... wartime conditions, researchers say , , TUESDAY, Feb. 17 (HealthDay ... be exacerbated by combat conditions in Iraq and Afghanistan ... evacuated for treatment, a new report finds. , In ... for poor morale and combat ineffectiveness, the researchers noted ...
Cached Medicine News:Health News:OMTEC Registration Opens - Education for a Competitive Advantage in Orthopaedics 2Health News:In flurry of studies, researcher details role of apples in inhibiting breast cancer 2Health News:What is the suppressing effect of the PPAR-gamma ligands on stomach cancer cells? 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 2Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 3Health News:Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 4Health News:Skin Woes Take Toll on U.S. Combat Troops 2Health News:Skin Woes Take Toll on U.S. Combat Troops 3
VG2 PLIF (Trapezoid) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit co...
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
... Corlok Allografts are unique corticocancellous ... face and a unique Dovetail geometry ... adjacent vertebrae. Corlok Allografts are processed ... spinal allograft implants. Specially designed instruments ...
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Medicine Products: